TOFFOLI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 4.304
EU - Europa 3.031
AS - Asia 2.563
SA - Sud America 355
AF - Africa 125
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.393
Nazione #
US - Stati Uniti d'America 4.187
SG - Singapore 847
PL - Polonia 843
IT - Italia 676
CN - Cina 517
VN - Vietnam 357
DE - Germania 276
BR - Brasile 272
SE - Svezia 266
HK - Hong Kong 222
FR - Francia 168
FI - Finlandia 134
GB - Regno Unito 127
BD - Bangladesh 112
KR - Corea 108
NL - Olanda 102
RU - Federazione Russa 99
IN - India 94
CA - Canada 71
UA - Ucraina 63
BG - Bulgaria 58
JP - Giappone 52
IE - Irlanda 51
TR - Turchia 44
MA - Marocco 42
PK - Pakistan 35
MX - Messico 27
ZA - Sudafrica 27
IR - Iran 26
AR - Argentina 25
BE - Belgio 23
ES - Italia 23
AT - Austria 20
CH - Svizzera 20
IQ - Iraq 20
SN - Senegal 19
ID - Indonesia 15
PH - Filippine 15
VE - Venezuela 15
AU - Australia 14
EC - Ecuador 13
CZ - Repubblica Ceca 11
RO - Romania 11
LB - Libano 10
SA - Arabia Saudita 10
TH - Thailandia 10
EG - Egitto 9
PT - Portogallo 9
CL - Cile 8
CO - Colombia 8
DK - Danimarca 8
JO - Giordania 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
MY - Malesia 6
SK - Slovacchia (Repubblica Slovacca) 6
TN - Tunisia 6
TW - Taiwan 6
BO - Bolivia 5
HU - Ungheria 5
KZ - Kazakistan 5
PY - Paraguay 5
RS - Serbia 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
GR - Grecia 4
LK - Sri Lanka 4
LT - Lituania 4
PR - Porto Rico 4
SY - Repubblica araba siriana 4
AZ - Azerbaigian 3
ET - Etiopia 3
HR - Croazia 3
KE - Kenya 3
NO - Norvegia 3
NP - Nepal 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
BZ - Belize 2
CG - Congo 2
IL - Israele 2
JM - Giamaica 2
LU - Lussemburgo 2
MD - Moldavia 2
MU - Mauritius 2
OM - Oman 2
PE - Perù 2
QA - Qatar 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
CY - Cipro 1
Totale 10.377
Città #
Warsaw 794
Ashburn 598
Singapore 528
Chandler 357
Fairfield 295
San Jose 251
Hong Kong 201
Woodbridge 200
Trieste 196
Houston 163
Dallas 158
Munich 152
Ann Arbor 146
Seattle 141
Wilmington 125
Cambridge 109
Beijing 106
Los Angeles 100
Seoul 99
Ho Chi Minh City 97
Helsinki 91
Council Bluffs 83
Hanoi 78
Princeton 76
Jacksonville 66
Hefei 61
Boardman 60
Chicago 60
Sofia 58
Santa Clara 56
Lauterbourg 53
New York 50
Columbus 46
Dublin 46
Frankfurt am Main 41
The Dalles 39
Moscow 38
Redmond 37
Zgierz 37
Milan 35
Tokyo 35
Rome 33
Casablanca 32
London 31
Buffalo 28
Dearborn 28
São Paulo 28
Dong Ket 26
Izmir 26
Shanghai 25
Brussels 23
Toronto 23
Phoenix 22
Dakar 19
Guangzhou 19
Düsseldorf 18
Amsterdam 17
Da Nang 17
Orem 17
Denver 16
Genoa 16
Lahore 16
Vienna 16
Atlanta 15
Chennai 15
Montreal 15
Turku 15
Bern 12
Falls Church 12
Johannesburg 12
Stockholm 12
Brooklyn 11
Haiphong 11
Manchester 11
San Francisco 11
Des Moines 10
Nuremberg 10
Paris 10
San Diego 10
Vancouver 10
Venezia 10
Boydton 9
Hải Dương 9
Mexico City 9
Zhengzhou 9
Andover 8
Brno 8
Kunming 8
Portsmouth 8
Quito 8
Redondo Beach 8
Sydney 8
Thái Nguyên 8
Turin 8
Venice 8
Washington 8
Amman 7
Chongqing 7
Dongguan 7
Hillsboro 7
Totale 6.822
Nome #
DNA Nanotechnology for Cancer Therapy 596
Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants 512
Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: Variables affecting specificity and effectiveness 476
Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia 423
Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin 375
Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy 342
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. 320
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 291
Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment 288
Label-Free Quantification of Anticancer Drug Imatinib in Human Plasma with Surface Enhanced Raman Spectroscopy 282
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 276
A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study 273
Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity 259
A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine 258
Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples 247
Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albumin 237
Common mutations in immunoglobulin VK3 light chain sequences from B-cells of HCV-related disorders 217
Biocompatible tailored zirconia mesoporous nanoparticles with high surface area for theranostic applications 212
Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations 210
Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: A first insight 208
Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models 204
Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine 200
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target 199
A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State 187
Differential proteomic analysis of hepatocellular carcinoma 183
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring 181
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy 177
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System 175
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model 170
A novel epigenetic machine learning model to define risk of progression for hepatocellular carcinoma patients 169
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma 167
An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma 163
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 160
New insight into therapies targeting angiogenesis in hepatocellular carcinoma 159
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies 154
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 152
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells. 147
Zebrafish: A Useful Animal Model for the Characterization of Drug-Loaded Polymeric NPs 145
A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma 142
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma 140
Stealth-Engineered Albumin-Coated Nanoparticles for Targeted Therapy: Effective Drug Delivery and Tumor Suppression in Xenograft-Zebrafish Model 139
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies 122
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 122
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma 113
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer 103
Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients 103
Oral Administration of Cancer Vaccines: Challenges and Future Perspectives 94
Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients 94
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies 92
Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles 9
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models 7
Totale 10.674
Categoria #
all - tutte 29.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.064


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202172 0 0 0 0 0 0 0 0 0 0 0 72
2021/2022605 21 20 41 21 9 96 41 12 68 47 29 200
2022/20231.230 94 160 110 151 98 172 48 116 137 60 57 27
2023/2024647 38 35 36 56 45 67 102 151 7 19 60 31
2024/20251.722 39 52 96 146 145 169 139 124 202 223 216 171
2025/20263.818 451 133 357 351 350 292 513 111 399 501 214 146
Totale 10.674